SWITZERLAND > India based Glenmark Pharmaceuticals is set to establish a new discovery center at Biopôle campus in Lausanne, Switzerland

glenmark logo To enhance its translational research capabilities, Glenmark Pharmaceuticals is set to open a new discovery center at the Biopôle campus in Lausanne, Switzerland. Glenmark Pharmaceuticals entered the Swiss market in 2004 and currently, Glenmark Pharmaceuticals employs around 160 people in its R&D center for biologics in the canton of Neuchâtel Glenmark will continue to invest in its existing Swiss site and More …

NEPAL > India based Tizig Pharma is set to invest Rs 351 million ($3.4 million) in cancer drug plant in Bhaktapur, Nepal

Tizig Pharma Pvt. Ltd. is set to invest Rs 351 million ($3.4 million) in Nepal for cancer drug production plant. As the cancer patients have increased in recent years, the India based company is set to invest in Nepal. Venkatesham Ambati, an Indian citizen, is the sole investor of the project. According to Khagendra Basnet, Director of the Department of More …

USA > France based Sanofi is set to acquire Bioverativ Inc. for approximately $11.6 billion

Sanofi logo For $105 per share in cash, Sanofi is set to acquire all the outstanding shares of Bioverativ representing an equity value of approximately $11.6 billion. Both biopharmaceutical companies focus on therapies for hemophilia and other rare blood disorders and the transaction was unanimously approved by Board of Directors of both Sanofi and Bioverativ. According to Olivier Brandicourt, Sanofi’s Chief Executive More …

USA > DanDrit Biotech USA, Inc. is set to acquire Enochian Biopharma Inc.

Dandrit logo Enochian Biopharma Inc. is to be acquired by DanDrit Biotech USA, Inc.  Enochian will enhance DanDrit’s research and development efforts as Enochian is developing an innovative proprietary technology in the field of HIV/AIDS. According to the acquisition terms the stockholders of Enochian shall receive: 50% of the number of shares of DanDrit’s common stock issued and outstanding upon the acquisition, More …

USA > Japan based Astellas Pharma Inc. acquires US based Mitobridge for $225 million (plus additional $225 million contingent on clinical development)

Astellas_Pharma_logo.svg Exercising its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function, Astellas Pharma Inc. will now wholly own US based Mitobridge. The 2013 partnership agreements between Astellas and Mitobridge were formulated to discover and develop compounds that More …

USA > US based Agena Bioscience and Germany based Molecular Health partner for MassArray Interpretation

agena bioscience Agena Bioscience and Molecular Health have entered into strategic partnership , even though specific terms of the agreement were not disclosed, it is known that Molecular Health will use its MH guide analysis platform to interpret Agena’s MassArray system raw generated data. The firm plan to cooperate and collaborate with their respective customer bases under the partnership and is part More …

JAPAN > US based Amgen to redeem Kirin’s shares the JV Kirin- Amgen making Kirin- Amgen a wholly-owned subsidiary of Amgen

Amgen logo Both Amgen and Kirin Holdings have agreed that Kirin-Amgen’s, Kirin shares will be bought by Amgen making Kirin- Amgen a wholly- owned subsidiary of Amgen. Established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the development of EPOGEN® (epoetin alfa) and later NEUPOGEN®(filgrastim), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Nplate® (romiplostim) and brodalumab. Kirin-Amgen also holds the intellectual property of More …

AUSTRIA > Singapore based Clearbridge BioMedics is expanding in EMEA and APAC regions through partnership with twelve new distributors to 26 new countries

Clearbridge biomedics logo ClearCell® FX1 System is now available in EMEA and APAC through partnership with twelve new distributors. Partnering with an international network of distributors who are leaders in biotechnology industry with qualified professionals and high quality and reliability in their services, Clearbridge BioMedics is introducing ClearCell® FX1 System in the following countries along with the distributor for the country: Distributor Countries Axon Lab More …